Systemic therapy for metastatic bladder cancer in 2016 and beyond

Keyphrases

• Systemic Therapy 100%
• Metastatic Bladder Cancer 100%
• Metastatic Urothelial Cancer 100%
• Patient Management 33%
• Poor Outcome 33%
• Therapeutic Target 33%
• Tumor-associated 33%
• Malignancy 33%
• Disease Progression 33%
• Standard of Care 33%
• Immune Escape 33%
• Difficult-to-treat 33%
• Innovative Approach 33%
• Somatic Alterations 33%
• Platinum Resistance 33%
• US FDA 33%
• Platinum-based Chemotherapy 33%
• Tumor Neovasculature 33%
• Preclinical Development 33%
• First-line Regimen 33%

Medicine and Dentistry

• Urothelial Cancer 100%
• Systemic Therapy 100%
• Metastatic Bladder Cancer 100%
• Neoplasm 66%
• Disease Exacerbation 33%
• Cancer 33%
• Somatics 33%
• Immunity 33%
• Chemotherapy 33%